SCHEMBL306916

SCHEMBL306916

[CH2]CC(C)(C)CCCC(C)(C)CCCC

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL78840 0.95
SCHEMBL1341717 0.90
SCHEMBL1973779 0.86 TSHR (0.37) TSHRALDH1A1
SCHEMBL1971804 0.84 TSHR (0.42) TSHR
SCHEMBL8755240 0.84 TSHR (0.42) TSHR
SCHEMBL10758322 0.84 TSHR (0.42) TSHR
SCHEMBL1971557 0.84 TSHR (0.42) TSHR
SCHEMBL22749064 0.84 TSHR (0.42) TSHR
SCHEMBL13583489 0.84 TSHR (0.42) TSHR
SCHEMBL11016467 0.84 TSHR (0.42) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10551345-B2 Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis APPLIED BIOSYSTEMS, LLC (US) 2020-02-04 US disclosed
EP-2496615-B1 ENVIRONMENTALLY FRIENDLY COLORANT COMPOSITIONS AND LATEX PAINTS/COATINGS MOORE BENJAMIN & CO (US) 2019-09-18 EP disclosed
US-20170356877-A1 POLY AND COPOLY(N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS APPLIED BIOSYSTEMS, LLC (US) 2017-12-14 US disclosed
US-9671367-B2 Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis APPLIED BIOSYSTEMS, LLC (US) 2017-06-06 US disclosed
EP-1814854-B1 CATIONIC CERAMIDES, AND ANALOGS THEREOF, AND THEIR USE FOR PREVENTING OR TREATING CANCER MUSC FOUND FOR RES DEV (US) 2015-02-25 EP disclosed
US-20140209461-A1 Poly and Copoly(N-vinylamide)s and Their Use In Capillary Electrophoresis APPLIED BIOSYSTEMS, LLC (US) 2014-07-31 US disclosed
EP-1660597-B1 COPOLYMER SURFACTANTS MOORE BENJAMIN & CO (US) 2014-03-05 EP disclosed
US-8329807-B2 Latex paint film resistant to adverse effects of water, and compositions and methods for making same COLUMBIA INSURANCE COMPANY (US) 2012-12-11 US disclosed
EP-2496615-A1 ENVIRONMENTALLY FRIENDLY COLORANT COMPOSITIONS AND LATEX PAINTS/COATINGS Columbia Insurance Company (US) 2012-09-12 EP disclosed
US-8093393-B2 Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2012-01-10 US disclosed
WO-2005035500-A2 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN EURO-CELTIQUE S.A. (LU) 2005-04-21 WO disclosed
US-6864261-B2 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2005-03-08 US disclosed
WO-2005019353-A2 COPOLYMER SURFACTANTS COLUMBIA INSURANCE COMPANY (US) 2005-03-03 WO disclosed
US-20050039635-A1 Copolymer surfactants BENJAMIN MOORE & CO. 2005-02-24 US disclosed
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides APPLIED BIOSYSTEMS, LLC 2005-02-03 US disclosed
WO-2004104054-A1 POLY AND COPOLY (N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS APPLERA CORPORATION (US) 2004-12-02 WO disclosed
US-20040127501-A1 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2004-07-01 US disclosed
WO-2004029044-A1 PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS EURO-CELTIQUE, S.A. (LU) 2004-04-08 WO disclosed
US-20040053914-A1 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. 2004-03-18 US disclosed
WO-2003093236-A1 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR EURO-CELTIQUE, S.A. (LU) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053914-A1 Therapeutic agents useful for treating pain SMN1; SMN2, OPRM1, PSEN1 TSHR 2139/4885ALDH1A1 416/4885LMNA 918/4885
US-20040127501-A1 Therapeutic agents useful for treating pain CACNA1A, GRIN2A, HTT TSHR 1813/4885ALDH1A1 516/4885LMNA 745/4885
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides POLI, PCNA, POLL TSHR 4259/4885ALDH1A1 3357/4885LMNA 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.